Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study.
Translational psychiatry October 31, 2025 Kristin L Dawson, Athena May Jean M Carangan, Jessica Klunder et al. 2 citations
Ketamine infusions reduced symptoms of depression and PTSD in 20 participants with major depressive disorder or posttraumatic stress disorder. The treatment also lowered biological age as measured by three epigenetic biomarkers (OMICmAge, GrimAge V2, and PhenoAge), indicating a potential reversal of accelerated aging linked to these conditions. Changes in underlying epigenetic biomarker proxies and surrogate protein markers accompanied the age reduction. The findings align with prior research on ketamine's effects and suggest that these epigenetic clocks can capture signals related to clinical improvements.